BEAM vs. RXRX
BEAM (Beam Therapeutics Inc.) and RXRX (Recursion Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, BEAM returned -22.62%/yr vs -37.05%/yr for RXRX. Their 0.62 correlation means they have sometimes moved together and sometimes differently.
Performance
BEAM vs. RXRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BEAM achieves a -7.94% return, which is significantly higher than RXRX's -26.65% return.
BEAM
- 1D
- -3.66%
- 1M
- -26.65%
- 6M
- -7.60%
- YTD
- -7.94%
- 1Y
- 35.53%
- 3Y*
- -3.63%
- 5Y*
- -22.62%
- 10Y*
- —
- ALL TIME*
- 0.95%
RXRX
- 1D
- -1.32%
- 1M
- -21.05%
- 6M
- -28.40%
- YTD
- -26.65%
- 1Y
- -47.18%
- 3Y*
- -39.89%
- 5Y*
- -37.05%
- 10Y*
- —
- ALL TIME*
- -35.29%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $49.96M | $71.79M | $70.50M | |
| $52.74M | $74.51M | $69.08M |
BEAM vs. RXRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
BEAM Beam Therapeutics Inc. | -7.94% | 11.77% | -8.89% | -30.40% | -50.92% | 8.01% |
RXRX Recursion Pharmaceuticals, Inc. | -26.65% | -39.50% | -31.44% | 27.89% | -54.99% | -42.90% |
Correlation
The correlation between BEAM and RXRX is 0.54, which is moderate. They have sometimes moved together and sometimes differently, sharing some price drivers without tracking each other closely.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.54 |
Correlation (3Y) Balances recent behavior with more history. | 0.61 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.64 |
Correlation (All Time) Calculated using the full available price history since Apr 16, 2021 | 0.62 |
The correlation between BEAM and RXRX has been stable across timeframes, ranging from 0.54 to 0.64 - a consistent structural relationship.
Fundamentals
BEAM:
$2.63B
RXRX:
$1.57B
BEAM:
-$0.63
RXRX:
-$1.12
BEAM:
19.99
RXRX:
22.67
BEAM:
2.26
RXRX:
1.55
BEAM:
$132.27M
RXRX:
$66.29M
BEAM:
-$84.92M
RXRX:
-$22.83M
BEAM:
-$68.39M
RXRX:
-$505.90M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BEAM vs. RXRX — Risk / Return Rank
BEAM
RXRX
BEAM vs. RXRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Beam Therapeutics Inc. (BEAM) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BEAM | RXRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.11 | ||
| Sortino ratioReturn per unit of downside risk | +2.15 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 0.90 | +0.23 |
| Calmar ratioReturn relative to maximum drawdown | 0.78 | -0.85 | +1.63 |
| Martin ratioReturn relative to average drawdown | 1.64 | -1.25 | +2.89 |
Loading charts...
Drawdowns
BEAM vs. RXRX - Drawdown Comparison
The maximum BEAM drawdown since its inception was -89.12%, roughly equal to the maximum RXRX drawdown of -93.13%. Use the drawdown chart below to compare losses from any high point for BEAM and RXRX.
Loading charts...
Drawdown Indicators
| BEAM | RXRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.12% | -93.13% | +4.01% |
Max Drawdown (1Y)Largest decline over 1 year | -38.15% | -58.17% | +20.02% |
Max Drawdown (3Y)Largest decline over 3 years | -67.74% | -81.70% | +13.96% |
Max Drawdown (5Y)Largest decline over 5 years | -87.25% | -90.95% | +3.70% |
Current DrawdownCurrent decline from peak | -80.90% | -92.74% | +11.84% |
Average DrawdownAverage peak-to-trough decline | -60.22% | -75.79% | +15.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.14% | 39.99% | -21.85% |
Volatility
BEAM vs. RXRX - Volatility Comparison
Beam Therapeutics Inc. (BEAM) has a higher volatility of 18.78% compared to Recursion Pharmaceuticals, Inc. (RXRX) at 17.39%. This indicates that BEAM's price experiences larger fluctuations and is considered to be riskier than RXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BEAM | RXRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.78% | 17.39% | +1.39% |
Volatility (6M)Calculated over the trailing 6-month period | 49.97% | 45.40% | +4.57% |
Volatility (1Y)Calculated over the trailing 1-year period | 75.16% | 69.61% | +5.55% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 75.00% | 93.18% | -18.18% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 80.54% | 92.91% | -12.37% |
Dividends
BEAM vs. RXRX - Dividend Comparison
Neither BEAM nor RXRX has paid dividends to shareholders.
Financials
BEAM vs. RXRX - Financials Comparison
This section allows you to compare key financial metrics between Beam Therapeutics Inc. and Recursion Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
BEAM and RXRX have a correlation of 0.54, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BEAM has higher volatility (18.78%) compared to RXRX (17.39%). In terms of maximum drawdown, BEAM dropped -89.12% vs RXRX's -93.13%.
BEAM currently has the higher Sharpe Ratio (0.39 vs -0.71), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BEAM and RXRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer